Featured Research

from universities, journals, and other organizations

New Tool Helps Physicians Tailor Hormone Therapy For High-risk Prostate Cancer Patients

Date:
September 27, 2008
Source:
Fox Chase Cancer Center
Summary:
Using one of the largest databases of prostate cancer outcomes in the United States, Fox Chase Cancer Center researchers have developed a prediction tool that uses a patient's clinical information to estimate the benefit of adding androgen deprivation therapy of various durations to radiation therapy.

Using one of the largest databases of prostate cancer outcomes in the United States, Fox Chase Cancer Center researchers have developed a prediction tool that uses a patient's clinical information to estimate the benefit of adding androgen deprivation therapy of various durations to radiation therapy.

Such hormone therapy has been shown to help radiation kill prostate cancer cells and improve survival in men at a high risk of recurrence, but it is associated with significant side effects. Even when the cancer has been characterized as high-risk, the degree of benefit from the addition of androgen deprivation can be quite variable.

"Studies have generally lumped patients into three levels of risk, and physicians have recommended hormone therapy based on these studies," says Niraj H. Pahlajani, a resident in the radiation oncology department at Fox Chase Cancer Center in Philadelphia. "Our experience tells us that prostate patients can't be lumped together into broad categories and expected to respond the same way to treatment even when they fall into similar risk-categories. Fortunately, we've been able to generate a nuanced prediction tool that incorporates disease burden and individualizes treatment recommendations. We can enter each patient's clinical information and estimate the probability of the cancer coming back using different durations of hormone therapy to determine the best course."

Pahlajani says other similar tools exist to predict cancer treatment outcomes, but none is as personalized and none has yet been used to estimate the gains from different lengths of hormone therapy. The Fox Chase researchers used two key factors derived via biopsy to identify subtle differences among those at intermediate to high-risk of recurrence. The two factors were the percent of cancer-positive tissue identified and the percent of that positive tissue with a Gleason grade of four or five.

"With this information, we're able to personalize each man's treatment by quantifying the optimal duration of hormones based on his individual factors," Pahlajani says.

Pahlajani presented the study supporting the tool at the 50th annual meeting of the American Society for Therapeutic Radiology and Oncology.

In addition to Pahlajani, co-authors include Brian L. Egleston, Mark K. Buyyounouski, David Y.T. Chen, and Eric M. Horwitz of Fox Chase Cancer Center, and Alan Pollack of University of Miami. The authors report no disclosures. Funding for this study was provided by the National Cancer Institute and Varian Medical Systems.


Story Source:

The above story is based on materials provided by Fox Chase Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

Fox Chase Cancer Center. "New Tool Helps Physicians Tailor Hormone Therapy For High-risk Prostate Cancer Patients." ScienceDaily. ScienceDaily, 27 September 2008. <www.sciencedaily.com/releases/2008/09/080923140635.htm>.
Fox Chase Cancer Center. (2008, September 27). New Tool Helps Physicians Tailor Hormone Therapy For High-risk Prostate Cancer Patients. ScienceDaily. Retrieved September 22, 2014 from www.sciencedaily.com/releases/2008/09/080923140635.htm
Fox Chase Cancer Center. "New Tool Helps Physicians Tailor Hormone Therapy For High-risk Prostate Cancer Patients." ScienceDaily. www.sciencedaily.com/releases/2008/09/080923140635.htm (accessed September 22, 2014).

Share This



More Health & Medicine News

Monday, September 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Liberia Pleads for Help to Fight Ebola

Liberia Pleads for Help to Fight Ebola

AP (Sep. 22, 2014) Liberia's finance minister is urging the international community to quickly follow through on pledges of cash to battle Ebola. Bodies are piling up in the capital Monrovia as the nation awaits more help. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Ebola Doctor Says Border Controls Critical

Ebola Doctor Says Border Controls Critical

AP (Sep. 22, 2014) A Florida doctor who helped fight the expanding Ebola outbreak in West Africa says the disease can be stopped, but only if nations quickly step up their response and make border control a priority. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Global Ebola Aid Increasing But Critics Say It's Late

Global Ebola Aid Increasing But Critics Say It's Late

Newsy (Sep. 21, 2014) More than 100 tons of medical supplies were sent to West Africa on Saturday, but aid workers say the global response is still sluggish. Video provided by Newsy
Powered by NewsLook.com
Sierra Leone in Lockdown to Control Ebola

Sierra Leone in Lockdown to Control Ebola

AP (Sep. 21, 2014) Sierra Leone residents remained in lockdown on Saturday as part of a massive effort to confine millions of people to their homes in a bid to stem the biggest Ebola outbreak in history. (Sept. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins